Gilead Sciences Inc.’s remdesivir was given an emergency use approval on Friday 1 May by the US Food and Drug Administration, the first drug to show benefits to patients with COVID-19 and a major step forward in tackling the pandemic.
The approval was based on results from the ACTT adaptive trial released on 29 April which showed that the antiviral...






